Novo Nordisk Highlights Progress in Obesity and Diabetes Portfolio, Announces Pill Launch Milestones
Novo Nordisk executives provided an update on their obesity and diabetes treatment pipeline, including key milestones for their oral semaglutide (Rybelsus) and…
Read article